Journal
CANCER
Volume 120, Issue 15, Pages 2282-2288Publisher
WILEY
DOI: 10.1002/cncr.28722
Keywords
cervical cancer; clinical trials; human papillomavirus; immunotherapy; anti-angiogenesis; screening; prevention
Categories
Ask authors/readers for more resources
Invasive cervical cancer remains an important global cause of death, despite the declining prevalence within the United States. Definitive therapies, including surgical resection of early-stage disease and chemoradiation for locally advanced disease, can be curative. For women who experience local or distant recurrences, the prognosis remains poor and better treatments are required. On July 18, 2013, The Gynecologic Oncology Group sponsored a State of the Science in Cervical Cancer Symposium with experts, researchers, clinicians, and interested stakeholders. This article summarize the progress that has been made, questions that require further investigation, and contemporary genomic findings and innovative treatments that may help inform the next generation of clinical trials for patients with cervical cancer. (C) 2014 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available